Predict tumor response and identify more patients for therapy with epigenomic biomarkers

Discover how integrating epigenomic insights can capture more patients for therapy and improve treatment selection criteria. While genomic alterations offer an important lens into tumor biology, they often tell only part of the story. In this webinar, experts will discuss how epigenetic changes can help identify novel biomarkers to deliver more precise and effective cancer therapies. You’ll hear about the latest data releases from AACR and ASCO 2025 on novel methylation applications such as cancer subtyping and improved deletion calling. Learn how you can partner with Guardant to leverage our methylation technology with Guardant Infinity and our real-world evidence data to develop more effective cancer therapies.

First name

Last name

Company

Job Title

Country

Which topics are you most interested in? (Select all that apply)

Biomarker Delivery

Clinical Trials

Companion Diagnostic Development

Commercialization

Other

Have you previously partnered or collaborated with Guardant Health?

Do you have any specific questions for our speakers or topics you hope we cover?

No cost to register, subject to confirmation

By registering for this event, you accept that you may receive direct communication from Endpoints News and/or the sponsor(s). View how we use your data here.

If you are experiencing problems with your registration, please try the Zoom registration page.

Jacob Berchuck

Assistant Professor, Hematology & Medical Oncology, Emory University School of Medicine

Dr. Jacob Berchuck is an Assistant Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. In addition to caring for men with prostate cancer at the Winship Cancer Institute of Emory University, Dr. Berchuck leads a translational cancer research lab that leverages novel liquid biopsy technologies to develop non-invasive biomarkers to guide treatment decisions and investigate the molecular mechanisms of therapeutic response and resistance.

Brad Sickler

Director, Translational Medicines Bioinformatics, Revolution Medicines

Revolution Medicines is a targeted medicine biotech focusing on developing and delivering innovative, targeted medicines for patients. Our current focus is on RAS-addicted cancers, which account for 30 percent of all new human cancer diagnosis. While at Revolution Medicines, built and managed the Translational Medicine informatics and data analysis team for (currently) 5 clinical phase I monotherapy trials, 10 phase I combo trails and 2 phase II trials.

Prior to Revolution medicines, worked at Illumina for 12 years, starting as a founding member of their clinical laboratory and was instrumental in developing many of the world’s first CLIA laboratory NGS assays as well as a plethora of other large-scale technologies there.

Sumit Kar

DIRECTOR, CLINICAL BIOMARKER DEVELOPMENT, TRANSLATIONAL MEDICINE, REVOLUTION MEDICINES

Dr. Sumit Kar is a clinical biomarker lead at Revolution Medicines. In his role, he develops biomarker strategies for early and late phase clinical studies for patients with RAS-addicted cancers. His expertise includes interrogating predictive, pharmacodynamic, and resistance clinical biomarkers in oncology drug development with circulating tumor DNA and other non-invasive methods.

Sumit received his PhD from the University of Nebraska Medical Center and previously worked in the field of clinical biomarker development at contract research organizations and other biopharma. Over his research career, Sumit has authored numerous peer-reviewed publications in the fields of biomarkers, bioanalysis, oncology, and metabolic diseases.

Matthew Ellis

Senior Vice President, Clinical Development, Guardant Health

Moderator

Jaime Green

Freelance Journalist & Science Writer

Jaime Green is a freelance science writer and author. Her work has appeared in The New York Times Magazine, The Atlantic, Aeon, Popular Science, Slate, Astrobites, and elsewhere. She is the series editor of The Best American Science and Nature Writing and author of The Possibility of Life: Science, Imagination, and Our Quest for Kinship in the Cosmos.